person · Reporting owner

SCHWARTZ BRIAN

Disclosed activity across 4 companies

Tapewire entity: 94776
SEC CIK: 0001431322

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Bio Green Med Solution, Inc.CYCC · Entity 8225	Director · Interim Chief Medical Officer	January 29, 2024	January 31, 2024
INFINITY PHARMACEUTICALS, INC.INFI · Entity 109802	Director	June 16, 2022	June 16, 2022
Vincerx Pharma, Inc.LSAC · Entity 84409	Director	March 05, 2020	March 09, 2020

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Bio Green Med Solution, Inc.

Report date January 29, 2024 · Filed January 31, 2024

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	15,205	Reported balance After 2024-01-29 transaction · row 1 1 source row Row 1 · 2024-01-29 · Grant · Acquired 12,500 · Balance 15,205 F1: Consists of restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock upon vesting. The RSUs vest in equal monthly installments beginning on February 29, 2024, subject to the Reporting Person's continued service through the applicable vesting date. F2: These securities were granted to Dr. Schwartz in connection with his appointment as interim Chief Medical Officer of Cyclacel Pharmaceuticals, Inc.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.28 · Expires 2034-01-29	Direct	12,500	Reported balance After 2024-01-29 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2024-01-29 · Grant · Acquired 12,500 · Balance 12,500 F2: These securities were granted to Dr. Schwartz in connection with his appointment as interim Chief Medical Officer of Cyclacel Pharmaceuticals, Inc. F3: The shares underlying the option vest in equal monthly installments beginning on February 29, 2024, subject to the Reporting Person's continued service through the applicable vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: Consists of restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock upon vesting. The RSUs vest in equal monthly installments beginning on February 29, 2024, subject to the Reporting Person's continued service through the applicable vesting date.

F2: These securities were granted to Dr. Schwartz in connection with his appointment as interim Chief Medical Officer of Cyclacel Pharmaceuticals, Inc.

F3: The shares underlying the option vest in equal monthly installments beginning on February 29, 2024, subject to the Reporting Person's continued service through the applicable vesting date.

INFINITY PHARMACEUTICALS, INC.

Report date June 16, 2022 · Filed June 16, 2022

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	30,919	Reported balance After 2022-06-16 transaction · row 1 1 source row Row 1 · 2022-06-16 · Grant · Acquired 30,919 · Balance 30,919 F1: Pursuant to the issuer's non-employee director compensation program, the reporting person has elected to receive this grant of shares in lieu of cash as payment of approximately 50% of such person's $42,000 annual retainer for service as a director.
Stock Option(right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.68 · Expires 2032-06-16	Direct	45,000	Reported balance After 2022-06-16 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2022-06-16 · Grant · Acquired 45,000 · Balance 45,000 F2: The option vests over a period of one year in equal quarterly installments beginning at the end of the first quarter after the date of grant, provided that the holder continues to serve as a director of the issuer.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to the issuer's non-employee director compensation program, the reporting person has elected to receive this grant of shares in lieu of cash as payment of approximately 50% of such person's $42,000 annual retainer for service as a director.

F2: The option vests over a period of one year in equal quarterly installments beginning at the end of the first quarter after the date of grant, provided that the holder continues to serve as a director of the issuer.

Vincerx Pharma, Inc.

Report date March 05, 2020 · Filed March 09, 2020

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	6,000	Reported balance Holding disclosure · report date 2020-03-05 · row 1 Holding and transaction disclosures are not merged. 1 source row Row 1 · Balance 6,000

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

ARQULE INC

Report date January 16, 2020 · Filed January 16, 2020

Section 16 reporting ended · disclosed 2020-01-16. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2020-01-16 transaction · row 1 1 source row Row 1 · 2020-01-16 · Other · Disposed 289,838 · Balance 0 F1: On December 6, 2019, ArQule, Inc. (the "Company") entered into an Agreement and Plan of Merger (as amended, supplemented or otherwise modified from time to time, the "Merger Agreement") with Merck Sharpe & Dohme Corp. ("MSD") and Argon Merger Sub, Inc., a wholly-owned subsidiary of MSD ("Merger Sub"), pursuant to which MSD acquired the Company by a tender offer for all shares of Company common stock (the "Offer") and a subsequent merger (the "Merger"), each of which became effective on January 16, 2020. Pursuant to the Merger Agreement, (i) Merger Sub purchased all shares of Company common stock that were validly tendered pursuant to the Offer for a cash payment equal to $20.00 per share (the "Offer Price") and (ii) all shares of Company common stock outstanding immediately prior to the effective time of the Merger (the "Effective Time"), were cancelled and converted automatically into the right to receive the Offer Price.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.16 · Expires 2025-01-20	Direct	Reported balance After 2020-01-16 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2020-01-16 · Disposition to issuer · Disposed 147,000 · Balance 0 F2: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common sotck subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.79 · Expires 2026-01-19	Direct	Reported balance After 2020-01-16 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2020-01-16 · Disposition to issuer · Disposed 108,000 · Balance 0 F2: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common sotck subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.53 · Expires 2027-01-17	Direct	Reported balance After 2020-01-16 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2020-01-16 · Disposition to issuer · Disposed 130,000 · Balance 0 F2: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common sotck subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.95 · Expires 2027-04-04	Direct	Reported balance After 2020-01-16 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2020-01-16 · Disposition to issuer · Disposed 260,000 · Balance 0 F2: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common sotck subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.75 · Expires 2028-01-16	Direct	Reported balance After 2020-01-16 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2020-01-16 · Disposition to issuer · Disposed 107,900 · Balance 0 F2: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common sotck subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.48 · Expires 2028-05-08	Direct	Reported balance After 2020-01-16 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2020-01-16 · Disposition to issuer · Disposed 40,000 · Balance 0 F2: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common sotck subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.48 · Expires 2028-07-23	Direct	Reported balance After 2020-01-16 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2020-01-16 · Disposition to issuer · Disposed 65,000 · Balance 0 F2: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common sotck subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.68 · Expires 2029-01-15	Direct	Reported balance After 2020-01-16 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2020-01-16 · Disposition to issuer · Disposed 314,050 · Balance 0 F2: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common sotck subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.70 · Expires 2021-01-24	Direct	Reported balance After 2020-01-16 transaction · row 10 Instrument identity requires review; Table II rows are not merged. 1 source row Row 10 · 2020-01-16 · Disposition to issuer · Disposed 140,000 · Balance 0 F2: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common sotck subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.95 · Expires 2022-02-01	Direct	Reported balance After 2020-01-16 transaction · row 11 Instrument identity requires review; Table II rows are not merged. 1 source row Row 11 · 2020-01-16 · Disposition to issuer · Disposed 12,578 · Balance 0 F2: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common sotck subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.51 · Expires 2023-01-14	Direct	Reported balance After 2020-01-16 transaction · row 12 Instrument identity requires review; Table II rows are not merged. 1 source row Row 12 · 2020-01-16 · Disposition to issuer · Disposed 21,376 · Balance 0 F2: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common sotck subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.57 · Expires 2024-01-22	Direct	Reported balance After 2020-01-16 transaction · row 13 Instrument identity requires review; Table II rows are not merged. 1 source row Row 13 · 2020-01-16 · Disposition to issuer · Disposed 106,500 · Balance 0 F2: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common sotck subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration.

Filing footnotes · ownership attribution and instrument terms

F1: On December 6, 2019, ArQule, Inc. (the "Company") entered into an Agreement and Plan of Merger (as amended, supplemented or otherwise modified from time to time, the "Merger Agreement") with Merck Sharpe & Dohme Corp. ("MSD") and Argon Merger Sub, Inc., a wholly-owned subsidiary of MSD ("Merger Sub"), pursuant to which MSD acquired the Company by a tender offer for all shares of Company common stock (the "Offer") and a subsequent merger (the "Merger"), each of which became effective on January 16, 2020. Pursuant to the Merger Agreement, (i) Merger Sub purchased all shares of Company common stock that were validly tendered pursuant to the Offer for a cash payment equal to $20.00 per share (the "Offer Price") and (ii) all shares of Company common stock outstanding immediately prior to the effective time of the Merger (the "Effective Time"), were cancelled and converted automatically into the right to receive the Offer Price.

F2: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common sotck subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
January 29, 2024 Filed Jan 31, 2024 21:56 UTC	Bio Green Med Solution, Inc. CYCC · Entity 8225	GrantStock Option (right to buy) · Derivative	12,500	$0.00 Strike: $2.28	$0.00	Disclosure SEC source: 0001104659-24-008862 · tm244773-1_4seq1.xml · derivative · entry 2 SCHWARTZ BRIAN · CIK 0001431322 · Director · Interim Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2034-01-29 F2 · price: These securities were granted to Dr. Schwartz in connection with his appointment as interim Chief Medical Officer of Cyclacel Pharmaceuticals, Inc. F3 · derivative.exercise_date: The shares underlying the option vest in equal monthly installments beginning on February 29, 2024, subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document
January 29, 2024 Filed Jan 31, 2024 21:56 UTC	Bio Green Med Solution, Inc. CYCC · Entity 8225	GrantCommon Stock	12,500	$0.00	$0.00	Disclosure SEC source: 0001104659-24-008862 · tm244773-1_4seq1.xml · nonDerivative · entry 1 SCHWARTZ BRIAN · CIK 0001431322 · Director · Interim Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,205 F1 · shares: Consists of restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock upon vesting. The RSUs vest in equal monthly installments beginning on February 29, 2024, subject to the Reporting Person's continued service through the applicable vesting date. F2 · price: These securities were granted to Dr. Schwartz in connection with his appointment as interim Chief Medical Officer of Cyclacel Pharmaceuticals, Inc. Read SEC document
June 30, 2023 Filed Jul 3, 2023 20:55 UTC	Bio Green Med Solution, Inc. CYCC · Entity 8225	GrantStock Option (right to buy) · Derivative	42,438	$0.00 Strike: $0.59	$0.00	Disclosure SEC source: 0001104659-23-077650 · tm2320411-1_4seq1.xml · derivative · entry 2 SCHWARTZ BRIAN · CIK 0001431322 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,438 Underlying: Common Stock · 42,438 shares Expires 2033-06-30 F2 · price: These securities were granted to Dr. Schwartz for his services as a member of the board of directors of Cyclacel Pharmaceuticals, Inc. Read SEC document
June 30, 2023 Filed Jul 3, 2023 20:55 UTC	Bio Green Med Solution, Inc. CYCC · Entity 8225	GrantCommon Stock	21,219	$0.00	$0.00	Disclosure SEC source: 0001104659-23-077650 · tm2320411-1_4seq1.xml · nonDerivative · entry 1 SCHWARTZ BRIAN · CIK 0001431322 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,602 F1 · shares: The reporting person received an award of 21,219 restricted stock units on June 30, 2023, which shall vest in full on June 30, 2024. F2 · price: These securities were granted to Dr. Schwartz for his services as a member of the board of directors of Cyclacel Pharmaceuticals, Inc. Read SEC document
June 16, 2022 Filed Jun 16, 2022 20:32 UTC	INFINITY PHARMACEUTICALS, INC. INFI · Entity 109802	GrantStock Option(right to buy) · Derivative	45,000	$0.00 Strike: $0.68	$0.00	Disclosure SEC source: 0001140361-22-023308 · form4.xml · derivative · entry 2 SCHWARTZ BRIAN · CIK 0001431322 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 45,000 shares Expires 2032-06-16 F2 · derivative.exercise_date: The option vests over a period of one year in equal quarterly installments beginning at the end of the first quarter after the date of grant, provided that the holder continues to serve as a director of the issuer. Read SEC document
June 16, 2022 Filed Jun 16, 2022 20:32 UTC	INFINITY PHARMACEUTICALS, INC. INFI · Entity 109802	GrantCommon Stock	30,919	$0.68	$20,994.00	Disclosure SEC source: 0001140361-22-023308 · form4.xml · nonDerivative · entry 1 SCHWARTZ BRIAN · CIK 0001431322 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,919 F1 · shares: Pursuant to the issuer's non-employee director compensation program, the reporting person has elected to receive this grant of shares in lieu of cash as payment of approximately 50% of such person's $42,000 annual retainer for service as a director. Read SEC document
June 14, 2022 Filed Jun 16, 2022 20:11 UTC	Bio Green Med Solution, Inc. CYCC · Entity 8225	GrantStock Option (right to buy) · Derivative	31,645	$0.00 Strike: $1.11	$0.00	Disclosure SEC source: 0001104659-22-071895 · tm2218645-3_4seq1.xml · derivative · entry 2 SCHWARTZ BRIAN · CIK 0001431322 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,645 Underlying: Common Stock · 31,645 shares Expires 2032-06-14 F2 · price: These options were granted to Dr. Schwartz for his services as a member of the board of directors of Cyclacel Pharmaceuticals, Inc. Read SEC document
June 14, 2022 Filed Jun 16, 2022 20:11 UTC	Bio Green Med Solution, Inc. CYCC · Entity 8225	GrantCommon Stock	15,822	$0.00	$0.00	Disclosure SEC source: 0001104659-22-071895 · tm2218645-3_4seq1.xml · nonDerivative · entry 1 SCHWARTZ BRIAN · CIK 0001431322 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,383 F1 · shares: The reporting person received an award of 15,822 restricted stock units on June 14, 2022, which shall vest in full on June 14, 2023. Read SEC document
September 07, 2021 Filed Sep 10, 2021 12:35 UTC	INFINITY PHARMACEUTICALS, INC. INFI · Entity 109802	GrantStock Option (right to buy) · Derivative	60,000	$0.00 Strike: $3.75	$0.00	Disclosure SEC source: 0001140361-21-030894 · form4.xml · derivative · entry 1 SCHWARTZ BRIAN · CIK 0001431322 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2031-09-07 F1 · derivative.exercise_date: . The option vests as to 1/8th of the total number of shares on September 30, 2021 and as to 1/8th of the total number of shares at the end of each calendar quarter thereafter, provided that the Reporting Person continues to serve as a director of the Issuer. Read SEC document
June 15, 2021 Filed Jun 17, 2021 20:07 UTC	Bio Green Med Solution, Inc. CYCC · Entity 8225	GrantStock Option (right to buy) · Derivative	2,374	$0.00 Strike: $6.69	$0.00	Disclosure SEC source: 0001104659-21-082597 · tm2119990d1_4.xml · derivative · entry 4 SCHWARTZ BRIAN · CIK 0001431322 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,122 Underlying: Common Stock · 2,374 shares Expires 2031-06-15 F3 · price: These options were granted to Dr. Schwartz for his services as a member of the board of directors of Cyclacel Pharmaceuticals, Inc. Read SEC document
June 15, 2021 Filed Jun 17, 2021 20:07 UTC	Bio Green Med Solution, Inc. CYCC · Entity 8225	GrantStock Option (right to buy) · Derivative	4,748	$0.00 Strike: $6.69	$0.00	Disclosure SEC source: 0001104659-21-082597 · tm2119990d1_4.xml · derivative · entry 3 SCHWARTZ BRIAN · CIK 0001431322 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,122 Underlying: Common Stock · 4,748 shares Expires 2031-06-15 F3 · price: These options were granted to Dr. Schwartz for his services as a member of the board of directors of Cyclacel Pharmaceuticals, Inc. Read SEC document
June 15, 2021 Filed Jun 17, 2021 20:07 UTC	Bio Green Med Solution, Inc. CYCC · Entity 8225	GrantCommon Stock	1,187	$0.00	$0.00	Disclosure SEC source: 0001104659-21-082597 · tm2119990d1_4.xml · nonDerivative · entry 2 SCHWARTZ BRIAN · CIK 0001431322 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,561 F2 · shares: The reporting person received an award of 1,187 restricted stock units on June 15, 2021, which shall vest in three equal installments on June 15, 2022, June 15, 2023, and June 15, 2024. Read SEC document
June 15, 2021 Filed Jun 17, 2021 20:07 UTC	Bio Green Med Solution, Inc. CYCC · Entity 8225	GrantCommon Stock	2,374	$0.00	$0.00	Disclosure SEC source: 0001104659-21-082597 · tm2119990d1_4.xml · nonDerivative · entry 1 SCHWARTZ BRIAN · CIK 0001431322 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,561 F1 · shares: The reporting person received an award of 2,374 restricted stock units on June 15, 2021, which shall vest in full on June 15, 2022. Read SEC document
December 17, 2020 Filed Dec 21, 2020 21:48 UTC	Bio Green Med Solution, Inc. CYCC · Entity 8225	GrantStock Option (right to buy) · Derivative	5,200	$0.00 Strike: $4.13	$0.00	Disclosure SEC source: 0001104659-20-138095 · tm2039008-2_4seq1.xml · derivative · entry 1 SCHWARTZ BRIAN · CIK 0001431322 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,200 Underlying: Common Stock · 5,200 shares Expires 2030-12-17 F1 · security: These options were granted to Dr. Schwartz for his services as a member of the board of directors of Cyclacel Pharmaceuticals, Inc. Read SEC document
January 16, 2020 Filed Jan 16, 2020 15:55 UTC	ARQULE INC ARQL · Entity 11927	Disposition to issuerStock Option (Right to Buy) · Derivative	106,500	Not disclosed Strike: $2.57	Not disclosed	Disclosure SEC source: 0001104659-20-004714 · tm203607d2_4.xml · derivative · entry 13 SCHWARTZ BRIAN · CIK 0001431322 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 106,500 shares Expires 2024-01-22 F2 · price: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common sotck subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration. F2 · derivative.exercise_date: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common sotck subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration. Read SEC document
January 16, 2020 Filed Jan 16, 2020 15:55 UTC	ARQULE INC ARQL · Entity 11927	Disposition to issuerStock Option (Right to Buy) · Derivative	21,376	Not disclosed Strike: $2.51	Not disclosed	Disclosure SEC source: 0001104659-20-004714 · tm203607d2_4.xml · derivative · entry 12 SCHWARTZ BRIAN · CIK 0001431322 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 21,376 shares Expires 2023-01-14 F2 · price: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common sotck subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration. F2 · derivative.exercise_date: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common sotck subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration. Read SEC document
January 16, 2020 Filed Jan 16, 2020 15:55 UTC	ARQULE INC ARQL · Entity 11927	Disposition to issuerStock Option (Right to Buy) · Derivative	12,578	Not disclosed Strike: $7.95	Not disclosed	Disclosure SEC source: 0001104659-20-004714 · tm203607d2_4.xml · derivative · entry 11 SCHWARTZ BRIAN · CIK 0001431322 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,578 shares Expires 2022-02-01 F2 · price: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common sotck subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration. F2 · derivative.exercise_date: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common sotck subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration. Read SEC document
January 16, 2020 Filed Jan 16, 2020 15:55 UTC	ARQULE INC ARQL · Entity 11927	Disposition to issuerStock Option (Right to Buy) · Derivative	140,000	Not disclosed Strike: $6.70	Not disclosed	Disclosure SEC source: 0001104659-20-004714 · tm203607d2_4.xml · derivative · entry 10 SCHWARTZ BRIAN · CIK 0001431322 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 140,000 shares Expires 2021-01-24 F2 · price: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common sotck subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration. F2 · derivative.exercise_date: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common sotck subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration. Read SEC document
January 16, 2020 Filed Jan 16, 2020 15:55 UTC	ARQULE INC ARQL · Entity 11927	Disposition to issuerStock Option (Right to Buy) · Derivative	314,050	Not disclosed Strike: $3.68	Not disclosed	Disclosure SEC source: 0001104659-20-004714 · tm203607d2_4.xml · derivative · entry 9 SCHWARTZ BRIAN · CIK 0001431322 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 314,050 shares Expires 2029-01-15 F2 · price: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common sotck subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration. F2 · derivative.exercise_date: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common sotck subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration. Read SEC document
January 16, 2020 Filed Jan 16, 2020 15:55 UTC	ARQULE INC ARQL · Entity 11927	Disposition to issuerStock Option (Right to Buy) · Derivative	65,000	Not disclosed Strike: $5.48	Not disclosed	Disclosure SEC source: 0001104659-20-004714 · tm203607d2_4.xml · derivative · entry 8 SCHWARTZ BRIAN · CIK 0001431322 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 65,000 shares Expires 2028-07-23 F2 · price: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common sotck subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration. F2 · derivative.exercise_date: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common sotck subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration. Read SEC document
January 16, 2020 Filed Jan 16, 2020 15:55 UTC	ARQULE INC ARQL · Entity 11927	Disposition to issuerStock Option (Right to Buy) · Derivative	40,000	Not disclosed Strike: $2.48	Not disclosed	Disclosure SEC source: 0001104659-20-004714 · tm203607d2_4.xml · derivative · entry 7 SCHWARTZ BRIAN · CIK 0001431322 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 40,000 shares Expires 2028-05-08 F2 · price: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common sotck subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration. F2 · derivative.exercise_date: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common sotck subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration. Read SEC document
January 16, 2020 Filed Jan 16, 2020 15:55 UTC	ARQULE INC ARQL · Entity 11927	Disposition to issuerStock Option (Right to Buy) · Derivative	107,900	Not disclosed Strike: $1.75	Not disclosed	Disclosure SEC source: 0001104659-20-004714 · tm203607d2_4.xml · derivative · entry 6 SCHWARTZ BRIAN · CIK 0001431322 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 107,900 shares Expires 2028-01-16 F2 · price: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common sotck subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration. F2 · derivative.exercise_date: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common sotck subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration. Read SEC document
January 16, 2020 Filed Jan 16, 2020 15:55 UTC	ARQULE INC ARQL · Entity 11927	Disposition to issuerStock Option (Right to Buy) · Derivative	260,000	Not disclosed Strike: $0.95	Not disclosed	Disclosure SEC source: 0001104659-20-004714 · tm203607d2_4.xml · derivative · entry 5 SCHWARTZ BRIAN · CIK 0001431322 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 260,000 shares Expires 2027-04-04 F2 · price: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common sotck subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration. F2 · derivative.exercise_date: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common sotck subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration. Read SEC document
January 16, 2020 Filed Jan 16, 2020 15:55 UTC	ARQULE INC ARQL · Entity 11927	Disposition to issuerStock Option (Right to Buy) · Derivative	130,000	Not disclosed Strike: $1.53	Not disclosed	Disclosure SEC source: 0001104659-20-004714 · tm203607d2_4.xml · derivative · entry 4 SCHWARTZ BRIAN · CIK 0001431322 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 130,000 shares Expires 2027-01-17 F2 · price: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common sotck subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration. F2 · derivative.exercise_date: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common sotck subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration. Read SEC document
January 16, 2020 Filed Jan 16, 2020 15:55 UTC	ARQULE INC ARQL · Entity 11927	Disposition to issuerStock Option (Right to Buy) · Derivative	108,000	Not disclosed Strike: $1.79	Not disclosed	Disclosure SEC source: 0001104659-20-004714 · tm203607d2_4.xml · derivative · entry 3 SCHWARTZ BRIAN · CIK 0001431322 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 108,000 shares Expires 2026-01-19 F2 · price: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common sotck subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration. F2 · derivative.exercise_date: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common sotck subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration. Read SEC document
January 16, 2020 Filed Jan 16, 2020 15:55 UTC	ARQULE INC ARQL · Entity 11927	Disposition to issuerStock Option (Right to Buy) · Derivative	147,000	Not disclosed Strike: $1.16	Not disclosed	Disclosure SEC source: 0001104659-20-004714 · tm203607d2_4.xml · derivative · entry 2 SCHWARTZ BRIAN · CIK 0001431322 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 147,000 shares Expires 2025-01-20 F2 · price: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common sotck subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration. F2 · derivative.exercise_date: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common sotck subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration. Read SEC document
January 16, 2020 Filed Jan 16, 2020 15:55 UTC	ARQULE INC ARQL · Entity 11927	OtherCommon Stock	289,838	$20.00	$5,796,760.00	Disclosure SEC source: 0001104659-20-004714 · tm203607d2_4.xml · nonDerivative · entry 1 SCHWARTZ BRIAN · CIK 0001431322 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: On December 6, 2019, ArQule, Inc. (the "Company") entered into an Agreement and Plan of Merger (as amended, supplemented or otherwise modified from time to time, the "Merger Agreement") with Merck Sharpe & Dohme Corp. ("MSD") and Argon Merger Sub, Inc., a wholly-owned subsidiary of MSD ("Merger Sub"), pursuant to which MSD acquired the Company by a tender offer for all shares of Company common stock (the "Offer") and a subsequent merger (the "Merger"), each of which became effective on January 16, 2020. Pursuant to the Merger Agreement, (i) Merger Sub purchased all shares of Company common stock that were validly tendered pursuant to the Offer for a cash payment equal to $20.00 per share (the "Offer Price") and (ii) all shares of Company common stock outstanding immediately prior to the effective time of the Merger (the "Effective Time"), were cancelled and converted automatically into the right to receive the Offer Price. Read SEC document
December 18, 2019 Filed Dec 20, 2019 16:08 UTC	ARQULE INC ARQL · Entity 11927	Exercise / conversionStock Options (Right to Buy) · Derivative	100,000	$0.00 Strike: $1.79	$0.00	Disclosure SEC source: 0001104659-19-074982 · tm1926797d1_4.xml · derivative · entry 9 SCHWARTZ BRIAN · CIK 0001431322 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 100,000 shares Expires 2026-01-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
December 18, 2019 Filed Dec 20, 2019 16:08 UTC	ARQULE INC ARQL · Entity 11927	Exercise / conversionStock Options (Right to Buy) · Derivative	64,124	$0.00 Strike: $2.51	$0.00	Disclosure SEC source: 0001104659-19-074982 · tm1926797d1_4.xml · derivative · entry 8 SCHWARTZ BRIAN · CIK 0001431322 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 64,124 shares Expires 2023-01-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
December 18, 2019 Filed Dec 20, 2019 16:08 UTC	ARQULE INC ARQL · Entity 11927	Exercise / conversionStock Options (Right to Buy) · Derivative	96,922	$0.00 Strike: $7.95	$0.00	Disclosure SEC source: 0001104659-19-074982 · tm1926797d1_4.xml · derivative · entry 7 SCHWARTZ BRIAN · CIK 0001431322 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 96,922 shares Expires 2022-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
December 18, 2019 Filed Dec 20, 2019 16:08 UTC	ARQULE INC ARQL · Entity 11927	Exercise / conversionStock Options (Right to Buy) · Derivative	90,000	$0.00 Strike: $3.42	$0.00	Disclosure SEC source: 0001104659-19-074982 · tm1926797d1_4.xml · derivative · entry 6 SCHWARTZ BRIAN · CIK 0001431322 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 90,000 shares Expires 2020-01-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
December 18, 2019 Filed Dec 20, 2019 16:08 UTC	ARQULE INC ARQL · Entity 11927	Tax withholdingCommon Stock	178,495	$20.11	$3,589,534.45	Disclosure SEC source: 0001104659-19-074982 · tm1926797d1_4.xml · nonDerivative · entry 5 SCHWARTZ BRIAN · CIK 0001431322 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 289,838 F1 · balance_after: The Reporting Person satisfied the exercise price and applicable tax withholding by electing to have the Company retain shares otherwise issuable upon exercise of the options. No shares were sold into the market as part of this transaction, and the Reporting Person continues to hold the net shares realized from the option exercise. Read SEC document
December 18, 2019 Filed Dec 20, 2019 16:08 UTC	ARQULE INC ARQL · Entity 11927	Exercise / conversionCommon Stock	100,000	$1.79	$179,000.00	Disclosure SEC source: 0001104659-19-074982 · tm1926797d1_4.xml · nonDerivative · entry 4 SCHWARTZ BRIAN · CIK 0001431322 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 468,333 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
December 18, 2019 Filed Dec 20, 2019 16:08 UTC	ARQULE INC ARQL · Entity 11927	Exercise / conversionCommon Stock	64,124	$2.51	$160,951.24	Disclosure SEC source: 0001104659-19-074982 · tm1926797d1_4.xml · nonDerivative · entry 3 SCHWARTZ BRIAN · CIK 0001431322 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 368,333 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
December 18, 2019 Filed Dec 20, 2019 16:08 UTC	ARQULE INC ARQL · Entity 11927	Exercise / conversionCommon Stock	96,922	$7.95	$770,529.90	Disclosure SEC source: 0001104659-19-074982 · tm1926797d1_4.xml · nonDerivative · entry 2 SCHWARTZ BRIAN · CIK 0001431322 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 304,209 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
December 18, 2019 Filed Dec 20, 2019 16:08 UTC	ARQULE INC ARQL · Entity 11927	Exercise / conversionCommon Stock	90,000	$3.42	$307,800.00	Disclosure SEC source: 0001104659-19-074982 · tm1926797d1_4.xml · nonDerivative · entry 1 SCHWARTZ BRIAN · CIK 0001431322 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 207,287 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
March 12, 2019 Filed Mar 14, 2019 16:35 UTC	ARQULE INC ARQL · Entity 11927	GrantEmployee Stock Options · Derivative	130,000	$0.00 Strike: $0.95	$0.00	Disclosure SEC source: 0001019695-19-000005 · primary_doc.xml · derivative · entry 1 SCHWARTZ BRIAN · CIK 0001431322 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,000 Underlying: Common Stock · 130,000 shares Expires 2027-04-03 F1 · shares: Represents earned shares with respect to a performance stock option granted on 4/4/2017 that contained performance requirements. The issuer's Board of Directors and Compensation, Nominating and Governance Committee certified as to the performance-goal attainment on 03/12/2019. The shares remain subject to time-based vesting in 12 quarterly installments from 4/4/2017. F1 · derivative.exercise_date: Represents earned shares with respect to a performance stock option granted on 4/4/2017 that contained performance requirements. The issuer's Board of Directors and Compensation, Nominating and Governance Committee certified as to the performance-goal attainment on 03/12/2019. The shares remain subject to time-based vesting in 12 quarterly installments from 4/4/2017. Read SEC document
January 15, 2019 Filed Jan 17, 2019 14:18 UTC	ARQULE INC ARQL · Entity 11927	GrantEmployee Stock Options · Derivative	314,050	$0.00 Strike: $3.68	$0.00	Disclosure SEC source: 0001019695-19-000003 · primary_doc.xml · derivative · entry 1 SCHWARTZ BRIAN · CIK 0001431322 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 314,050 Underlying: Common Stock · 314,050 shares Expires 2029-01-15 F1 · derivative.exercise_date: The options vest in four equal annual installments beginning on January 15, 2020. Read SEC document
July 23, 2018 Filed Jul 25, 2018 15:55 UTC	ARQULE INC ARQL · Entity 11927	GrantEmployee Stock Options · Derivative	65,000	$0.00 Strike: $5.48	$0.00	Disclosure SEC source: 0001144204-18-039883 · tv499267_4.xml · derivative · entry 1 SCHWARTZ BRIAN · CIK 0001431322 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Stock · 65,000 shares Expires 2028-07-23 F1 · derivative.exercise_date: The options vest in four equal annual installments beginning on July 23, 2019. Read SEC document
June 13, 2018 Filed Jun 14, 2018 09:27 UTC	ARQULE INC ARQL · Entity 11927	Exercise / conversionStock Options (Right to Buy) · Derivative	200,000	$0.00 Strike: $3.62	$0.00	Disclosure SEC source: 0001019695-18-000023 · primary_doc.xml · derivative · entry 3 SCHWARTZ BRIAN · CIK 0001431322 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 200,000 shares Expires 2018-07-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
June 13, 2018 Filed Jun 14, 2018 09:27 UTC	ARQULE INC ARQL · Entity 11927	Tax withholdingCommon Stock	148,569	$5.18	$769,587.42	Disclosure SEC source: 0001019695-18-000023 · primary_doc.xml · nonDerivative · entry 2 SCHWARTZ BRIAN · CIK 0001431322 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,169 F1 · balance_after: The Reporting Person exercised options that were scheduled to expire in July, 2018 during a trading blackout period. The Reporting Person satisfied the exercise price and applicable tax withholding by electing to have the Company retain shares otherwise issuable upon exercise of the options. No shares were sold into the market as part of this transaction, and the Reporting Person continues to hold the net shares realized from the option exercise. Read SEC document
June 13, 2018 Filed Jun 14, 2018 09:27 UTC	ARQULE INC ARQL · Entity 11927	Exercise / conversionCommon Stock	200,000	$3.62	$724,000.00	Disclosure SEC source: 0001019695-18-000023 · primary_doc.xml · nonDerivative · entry 1 SCHWARTZ BRIAN · CIK 0001431322 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 245,738 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
May 08, 2018 Filed May 11, 2018 16:01 UTC	ARQULE INC ARQL · Entity 11927	GrantEmployee Stock Options · Derivative	40,000	$0.00 Strike: $2.48	$0.00	Disclosure SEC source: 0001019695-18-000016 · primary_doc.xml · derivative · entry 1 SCHWARTZ BRIAN · CIK 0001431322 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2028-05-08 F1 · derivative.exercise_date: The options vest in four equal annual installments beginning on May 8, 2019. Read SEC document
January 16, 2018 Filed May 10, 2018 14:37 UTC	ARQULE INC ARQL · Entity 11927	GrantEmployee Stock Options · Derivative	107,900	$0.00 Strike: $1.75	$0.00	Disclosure SEC source: 0001019695-18-000010 · primary_doc.xml · derivative · entry 1 SCHWARTZ BRIAN · CIK 0001431322 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,900 Underlying: Common Stock · 107,900 shares Expires 2028-01-16 F1 · date: Granted on January 16, 2018, subject to stockholder approval received on May 8, 2018. F2 · derivative.exercise_date: The options vest in four equal annual installments beginning on January 16, 2019. Read SEC document
January 17, 2017 Filed Jan 18, 2017 16:23 UTC	ARQULE INC ARQL · Entity 11927	GrantEmployee Stock Options · Derivative	130,000	$0.00 Strike: $1.53	$0.00	Disclosure SEC source: 0001019695-17-000006 · primary_doc.xml · derivative · entry 2 SCHWARTZ BRIAN · CIK 0001431322 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,000 Underlying: Common Stock · 130,000 shares Expires 2027-01-17 F1 · derivative.exercise_date: The options vest in four equal annual installments beginning on January 17, 2018. Read SEC document
January 14, 2017 Filed Jan 18, 2017 16:23 UTC	ARQULE INC ARQL · Entity 11927	Tax withholdingCommon Stock	2,847	$1.58	$4,498.26	Disclosure SEC source: 0001019695-17-000006 · primary_doc.xml · nonDerivative · entry 1 SCHWARTZ BRIAN · CIK 0001431322 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,738 Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.